VTR

Ventas is a healthcare REIT with its core growth engine in senior housing operations (SHOP), a segment benefiting from favorable demographics and a multi-year occupancy recovery. Management has been leaning into SHOP through acquisitions/investment activity and positioning it as a majority contributor to NOI, which can widen the moat if operating execution stays strong. The main structural risk is that senior housing is more operationally complex than traditional triple-net leases, making results more sensitive to labor, pricing, and occupancy swings.

Financially, recent performance points to a healthier earnings trajectory: Ventas reported 2025 results with 9% normalized FFO per share growth and 15% same-store SHOP NOI growth, and guided to 2026 normalized FFO per share of $3.78–$3.88 (8% growth at the midpoint) alongside 13%–17% SHOP same-store cash NOI growth. Balance-sheet flexibility appears supported by ongoing access to unsecured debt markets, including a $500 million 5.0% senior notes issuance due 2036, though higher interest expense remains a real headwind as maturities refinance. Valuation is best framed on FFO rather than GAAP P/E (which screens elevated), and the stock increasingly trades as a “growth REIT,” leaving less room for execution missteps.

Over the next 12 months, the thesis is that accelerating SHOP cash NOI growth (occupancy gains plus RevPOR) can drive upside to FFO and support further dividend growth, with Q1 2026 results due after the close on April 27, 2026 as a near-term catalyst. Key risks are a slowdown in occupancy momentum, wage inflation pressuring margins, and rate-driven multiple compression if long yields rise. A secondary swing factor is the pace and pricing of acquisitions, which can be accretive but add leverage and integration risk.

Recommendation: HOLD. The operating recovery and 2026 FFO/SHOP NOI growth outlook are compelling, but rate sensitivity and a higher “growth REIT” valuation leave the risk/reward closer to balanced until execution is confirmed in 2026 results.